These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 12640841)

  • 1. Aprotinin: antifibrinolytic and anti-inflammatory mechanisms of action in cardiac surgery with cardiopulmonary bypass.
    Donahue MA; Price PM
    Dynamics; 2002; 13(3):16-23. PubMed ID: 12640841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aprotinin in cardiac surgery.
    Sodha NR; Boodhwani M; Bianchi C; Ramlawi B; Sellke FW
    Expert Rev Cardiovasc Ther; 2006 Mar; 4(2):151-60. PubMed ID: 16509811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of aprotinin and tranexamic acid on thrombin generation and fibrinolytic response after cardiac surgery.
    Kuitunen A; Hiippala S; Vahtera E; Rasi V; Salmenperä M
    Acta Anaesthesiol Scand; 2005 Oct; 49(9):1272-9. PubMed ID: 16146463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A propensity score case-control comparison of aprotinin and tranexamic acid in high-transfusion-risk cardiac surgery.
    Karkouti K; Beattie WS; Dattilo KM; McCluskey SA; Ghannam M; Hamdy A; Wijeysundera DN; Fedorko L; Yau TM
    Transfusion; 2006 Mar; 46(3):327-38. PubMed ID: 16533273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aprotinin in cardiac surgery: a review of conventional and novel mechanisms of action.
    McEvoy MD; Reeves ST; Reves JG; Spinale FG
    Anesth Analg; 2007 Oct; 105(4):949-62. PubMed ID: 17898372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of aprotinin (trasylol) on the inflammatory and thrombotic complications of conventional cardiopulmonary bypass surgery.
    Landis RC; Asimakopoulos G; Poullis M; Thompson R; Nourshargh S; Haskard DO; Taylor KM
    Heart Surg Forum; 2001; 4 Suppl 1():S35-9. PubMed ID: 11178306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does aprotinin influence the inflammatory response to cardiopulmonary bypass in patients?
    Schmartz D; Tabardel Y; Preiser JC; Barvais L; d'Hollander A; Duchateau J; Vincent JL
    J Thorac Cardiovasc Surg; 2003 Jan; 125(1):184-90. PubMed ID: 12539003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of nafamostat mesilate and minimal-dose aprotinin on blood-foreign surface interactions in cardiopulmonary bypass.
    Kaminishi Y; Hiramatsu Y; Watanabe Y; Yoshimura Y; Sakakibara Y
    Ann Thorac Surg; 2004 Feb; 77(2):644-50. PubMed ID: 14759453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aprotinin versus tranexamic acid: the controversy continues.
    Levy JH
    Transfusion; 2006 Mar; 46(3):319-20. PubMed ID: 16533270
    [No Abstract]   [Full Text] [Related]  

  • 10. Aprotinin: an update of its pharmacology and therapeutic use in open heart surgery and coronary artery bypass surgery.
    Peters DC; Noble S
    Drugs; 1999 Feb; 57(2):233-60. PubMed ID: 10188764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variability of plasma aprotinin concentrations in pediatric patients undergoing cardiac surgery.
    Oliver WC; Fass DN; Nuttall GA; Dearani JA; Schrader LM; Schroeder DR; Ereth MH; Puga FJ
    J Thorac Cardiovasc Surg; 2004 Jun; 127(6):1670-7. PubMed ID: 15173722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low dose aprotinin and low dose tranexamic acid in elective cardiac surgery with cardiopulmonary bypass.
    Waldow T; Krutzsch D; Wils M; Plötze K; Matschke K
    Clin Hemorheol Microcirc; 2009; 42(4):269-77. PubMed ID: 19628892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The effect of aprotinin and tranexamic acid on fibrinolysis and thrombin generation during cardiopulmonary bypass].
    Risch A; Dorscheid E; Stein G; Seyfert UT; Grundmann U
    Anaesthesist; 2000 Apr; 49(4):279-85. PubMed ID: 10840537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is reduced systemic heparinization justified with heparin-bonded bypass circuits in cardiac surgery?--Experience with and without aprotinin.
    Kipfer B; Englberger L; Gygax E; Nydegger U; Carrel T
    Transfus Apher Sci; 2003 Aug; 29(1):17-24. PubMed ID: 12877888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism of the preserving effect of aprotinin on platelet function and its use in cardiac surgery.
    Huang H; Ding W; Su Z; Zhang W
    J Thorac Cardiovasc Surg; 1993 Jul; 106(1):11-8. PubMed ID: 7686594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pump-prime aprotinin dose in cardiac surgery: appraisal of its effects on the hemostatic system.
    Rossi M; Storti S; Martinelli L; Varano C; Marra R; Zamparelli R; Possati G; Schiavello R
    J Cardiothorac Vasc Anesth; 1997 Dec; 11(7):835-9. PubMed ID: 9412880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic inflammation and cardiac surgery: an update.
    Asimakopoulos G
    Perfusion; 2001 Sep; 16(5):353-60. PubMed ID: 11565890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal dysfunction in cardiac surgery: identifying potential risk factors.
    Barnum JL; Sistino JJ
    Perfusion; 2009 Mar; 24(2):139-42. PubMed ID: 19654159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perioperative renal outcome in cardiac surgical patients with preoperative renal dysfunction: aprotinin versus epsilon aminocaproic acid.
    Maslow AD; Chaudrey A; Bert A; Schwartz C; Singh A
    J Cardiothorac Vasc Anesth; 2008 Feb; 22(1):6-15. PubMed ID: 18249324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, controlled trial of aprotinin in neonates undergoing open-heart surgery.
    Williams GD; Ramamoorthy C; Pentcheva K; Boltz MG; Kamra K; Reddy VM
    Paediatr Anaesth; 2008 Sep; 18(9):812-9. PubMed ID: 18768040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.